MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice

World Journal of Gastroenterology

Volumn 20, Issue 43, 2014, Pages 16227-16235

  Ohyama, Tatsuya ^a   Sato, Ken ^a   Yamazaki, Yuichi ^a   Hashizume, Hiroaki ^a   Horiguchi, Norio ^a   Kakizaki, Satoru ^a   Mori, Masatomo ^a   Kusano, Motoyasu ^b   Yamada, Masanobu ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adiponectin; AMP Activated protein kinase; Dipeptidyl peptidase 4 inhibitor; Hepatic steatosis; Microsomal triglyceride transfer protein; Ob ob mice

Indexed keywords

ACYL COENZYME A DESATURASE 1; ADIPONECTIN; ALANINE AMINOTRANSFERASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FATTY ACID SYNTHASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MK 0626; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, MOUSE; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, MOUSE; MK0626; TRIAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FAT CONTENT; FATTY LIVER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN BLOOD LEVEL; LIPID LIVER LEVEL; LIPID STORAGE; LIVER RESECTION; MALE; MOUSE; NONHUMAN; RADIATION RESPONSE; TEST MEAL; TREATMENT RESPONSE; ANIMAL; BLOOD; CELL PROTECTION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIPOGENESIS; LIVER; METABOLISM; MOUSE MUTANT; OBESITY; PATHOLOGY; SIGNAL TRANSDUCTION; TIME;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOMARKERS; CYTOPROTECTION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FATTY LIVER; GENE EXPRESSION REGULATION; LIPOGENESIS; LIVER; MALE; MICE, OBESE; OBESITY; SIGNAL TRANSDUCTION; TIME FACTORS; TRIAZOLES; TRIGLYCERIDES;

EID: 84912570421     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i43.16227     Document Type: Article

References (33)

1. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102].
2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913 [PMID: 10605628].
3. Meier JJ, Nauck MA. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab 2004; 18: 587-606 [PMID: 15533777].
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705 [PMID: 17098089].
5. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122: 531-544 [PMID: 11832466].
6. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165 [PMID: 16517403].
7. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835 [PMID: 8100523].
8. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004; 47: 4135-4141 [PMID: 15293982].
9. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMPactivated protein kinase. J Hepatol 2011; 54: 1214-1223 [PMID: 21145820 DOI: 10.1016/j.jhep.2010.09.032].
10. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR, Gagliardino JJ. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011; 120: 73-80 [PMID: 20795946 DOI: 10.1042/cs20100372].
11. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, Amo K, Aoki K, Morimoto C, Takeda E, Terauchi Y. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60: 1246-1257 [PMID: 21330637 DOI: 10.2337/db10-1338].
12. Akaslan SB, Degertekin CK, Yilmaz G, Cakir N, Arslan M, Toruner FB. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metab Syndr Relat Disord 2013; 11: 243-250 [PMID: 23544853 DOI: 10.1089/met.2012.0128].
13. Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, deCarvalho L, Aguila MB, Mandarim-de-Lacerda CA. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 2010; 119: 239-250 [PMID: 20415664 DOI: 10.1042/CS20100061].
14. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non- Alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103-2105 [PMID: 22024083 DOI: 10.5754/hge11263].
15. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-1161 [PMID: 7584987].
16. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-549 [PMID: 7624778].
17. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weightreducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546 [PMID: 7624777].
18. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-543 [PMID: 7624776].
19. Edmondson SD, Mastracchio A, Mathvink RJ, He J, Harper B, Park YJ, Beconi M, Di Salvo J, Eiermann GJ, He H, Leiting B, Leone JF, Levorse DA, Lyons K, Patel RA, Patel SB, Petrov A, Scapin G, Shang J, Roy RS, Smith A, Wu JK, Xu S, Zhu B, Thornberry NA, Weber AE. (2S, 3S)-3-Amino- 4-(3, 3-difluoropyrrolidin-1-yl)-N, N-dimethyl-4-oxo-2-(4-[1, 2, 4]triazolo[1, 5- A]-pyridin-6-ylphenyl)butanamide: A selective alpha- Amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2006; 49: 3614-3627 [PMID: 16759103].
20. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509 [PMID: 13428781].
21. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez- Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481 [PMID: 18819705 DOI: 10.1016/s0140-6736(08)61246-5.Epub- 2008Sep24].
22. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007; 9: 317-326 [PMID: 17705687].
23. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447 [PMID: 16776751].
24. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-181 [PMID: 16374859].
25. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007; 61: 171-180 [PMID: 17156104].
26. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007; 23: 1329-1339 [PMID: 17559733].
27. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 376-386 [PMID: 18355324 DOI: 10.1111/j.1463-1326.2008.00876. x.Epub2008Mar18].
28. Furuta Y, Horiguchi M, Sugaru E, Ono-Kishino M, Otani M, Sakai M, Masui Y, Tsuchida A, Sato Y, Takubo K, Hochigai H, Kimura H, Nakahira H, Nakagawa T, Taiji M. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice. Diabetes Obes Metab 2010; 12: 421-430 [PMID: 20415690].
29. Yanai H, Adachi H, Hamasaki H, Masui Y, Yoshikawa R, Moriyama S, Mishima S, Sako A. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: A chart-based analysis. J Clin Med Res 2012; 4: 251-258 [PMID: 22870172 DOI: 10.4021/jocmr975w.Epub2012Jul20].
30. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens) 2012; 11: 8-20 [PMID: 22450341].
31. Kirino Y, Sei M, Kawazoe K, Minakuchi K, Sato Y. Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people. Endocr J 2012; 59: 949-953 [PMID: 22785237].
32. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54: 3252-3257 [PMID: 16249452].
33. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: A euglycemic-hyperinsulinemic clamp study. Diabetes 2002; 51: 2677-2683 [PMID: 12196458].